# Corynebacterium diphtheriae and Corynebacterium ulcerans: development of EUCAST methods and generation of data on which to determine breakpoints

Anja Berger, E Badell, Jenny Åhman, Erika Matuschek, Nora Zidane, Gunnar

Kahlmeter, Andreas Sing, Sylvain Brisse

► To cite this version:

Anja Berger, E Badell, Jenny Åhman, Erika Matuschek, Nora Zidane, et al. Corynebacterium diphtheriae and Corynebacterium ulcerans: development of EUCAST methods and generation of data on which to determine breakpoints. Journal of Antimicrobial Chemotherapy, 2024, pp.dkae056. 10.1093/jac/dkae056. pasteur-04543684

HAL Id: pasteur-04543684

https://pasteur.hal.science/pasteur-04543684

Submitted on 12 Apr 2024

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
# Corynebacterium diphtheriae and Corynebacterium ulcerans: development of EUCAST methods and generation of data on which to determine breakpoints

Anja Berger, E Badell, Jenny Åhman, Erika Matuschek, Nora Zidane, Gunnar

Kahlmeter, Andreas Sing, Sylvain Brisse

► To cite this version:

Anja Berger, E Badell, Jenny Åhman, Erika Matuschek, Nora Zidane, et al. Corynebacterium diphtheriae and Corynebacterium ulcerans: development of EUCAST methods and generation of data on which to determine breakpoints. Journal of Antimicrobial Chemotherapy, 2024, pp.dkae056. 10.1093/jac/dkae056. pasteur-04543684

HAL Id: pasteur-04543684

https://pasteur.hal.science/pasteur-04543684v1

Submitted on 12 Apr 2024

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
# Corynebacterium diphtheriae and Corynebacterium ulcerans: development of EUCAST methods and generation of data on which to determine breakpoints

Anja Berger<fnref n="1" />†, Edgar Badell²,³†, Jenny Åhman⁴†, Erika Matuschek ID ⁴, Nora Zidane², Gunnar Kahlmeter⁴‡, Andreas Sing<fnref n="1" />‡ and Sylvain Brisse ID ²,³*‡

Received 6 December 2023; accepted 20 February 2024

**Background:** Evidence-based clinical susceptibility breakpoints have been lacking for antimicrobial agents used for diphtheria.

**Objectives:** We aimed to evaluate broth microdilution and disc diffusion methods and create a dataset of MIC values and inhibition zone diameters (ZDs) from which breakpoints could be determined.

**Methods:** We included 400 recent clinical isolates equally distributed by species (*Corynebacterium diphtheriae* and *Corynebacterium ulcerans*) and by national surveillance programmes (France and Germany). Non-duplicate toxigenic and non-toxigenic isolates were chosen to enable the inclusion of a diversity of susceptibility levels for the 13 agents tested. Broth microdilution and disc diffusion, using EUCAST methodology for fastidious organisms, were used.

**Results:** The distributions of MIC and ZD values were largely in agreement among methods and countries. Breakpoints to allow categorization of WT isolates as susceptible, i.e. susceptible (S) or isusceptible, increased exposure (I) were determined for 12 agents. The data supported a breakpoint for benzylpenicillin and amoxicillin of resistant (R) > 1 mg/L since WT isolates were inhibited by 1 mg/L or less. WT isolates were categorized as I (S ≤ 0.001 mg/L) for benzylpenicillin, emphasizing the need for increased exposure, and S (S ≤ 1 mg/L) for amoxicillin. Erythromycin breakpoints were set at S ≤ 0.06 mg/L and R > 0.06 mg/L. The corresponding ZD breakpoints were determined for all agents except amoxicillin, for which categorization was based on benzylpenicillin results.

**Conclusions:** This work provided a large set of antimicrobial susceptibility data for *C. diphtheriae* and *C. ulcerans*, using a harmonized methodology. The dataset allowed EUCAST and experts in the diphtheria field to develop evidence-based breakpoints in January 2023.

## Introduction

Diphtheria was a major scourge of humanity until the large-scale roll-out of vaccination.<fnref n="1" /> *Corynebacterium diphtheriae*, the classical agent of diphtheria, is highly transmissible among humans and causes outbreaks of potentially fatal respiratory disease. Cutaneous infections are endemic mainly in tropical areas, but also occasionally in underprivileged populations in other

regions.²⁻⁴ *Corynebacterium ulcerans* is a zoonotic agent of diphtheria that is most often transmitted from household cats and dogs, and can cause infections similar to classical diphtheria, with the important difference that it is not transmissible among humans.⁵

Classical diphtheria, caused by toxigenic *C. diphtheriae*, is currently re-emerging in multiple world regions. Large outbreaks are currently ongoing or have been recently observed, e.g. in Yemen,

<footnote n="1">¹National Consiliary Laboratory for Diphtheria, Bavarian Food and Health Authority (LGL), Oberschleissheim, Germany; ²Institut Pasteur, Université Paris Cité, Biodiversity and Epidemiology of Bacterial Pathogens, 25-28 rue du Docteur Roux, F-75724, Paris, France; ³Institut Pasteur, National Reference Center for Corynebacteria of the Diphtheriae Complex, Paris, France; ⁴EUCAST Development Laboratory (EDL), Växjö, Sweden</footnote>

<footnote>*Corresponding author. E-mail: sylvain.brisse@pasteur.fr</footnote>

<footnote>X @sylvainbrisse</footnote>

<footnote>†These authors contributed equally.</footnote>

<footnote>‡G.K., A.S. and S.B. co-supervised the work.</footnote>
**Corynebacterium diphtheriae and Corynebacterium ulcerans:**
development of EUCAST methods and generation of data on which to
determine breakpoints

Anja Berger<fnref n="1" />†, Edgar Badell²,³†, Jenny Åhman⁴†, Erika Matuschek ID ⁴, Nora Zidane², Gunnar Kahlmeter⁴‡,
Andreas Sing<fnref n="1" />‡ and Sylvain Brisse ID ²,³*‡

Received 6 December 2023; accepted 20 February 2024

**Background:** Evidence-based clinical susceptibility breakpoints have been lacking for antimicrobial agents used for diphtheria.

**Objectives:** We aimed to evaluate broth microdilution and disc diffusion methods and create a dataset of MIC values and inhibition zone diameters (ZDs) from which breakpoints could be determined.

**Methods:** We included 400 recent clinical isolates equally distributed by species (*Corynebacterium diphtheriae* and *Corynebacterium ulcerans*) and by national surveillance programmes (France and Germany). Non-duplicate toxigenic and non-toxigenic isolates were chosen to enable the inclusion of a diversity of susceptibility levels for the 13 agents tested. Broth microdilution and disc diffusion, using EUCAST methodology for fastidious organisms, were used.

**Results:** The distributions of MIC and ZD values were largely in agreement among methods and countries. Breakpoints to allow categorization of WT isolates as susceptible, i.e. susceptible (S) or isusceptible, increased exposure (I) were determined for 12 agents. The data supported a breakpoint for benzylpenicillin and amoxicillin of resistant (R) > 1 mg/L since WT isolates were inhibited by 1 mg/L or less. WT isolates were categorized as I (S ≤ 0.001 mg/L) for benzylpenicillin, emphasizing the need for increased exposure, and S (S ≤ 1 mg/L) for amoxicillin. Erythromycin breakpoints were set at S ≤ 0.06 mg/L and R > 0.06 mg/L. The corresponding ZD breakpoints were determined for all agents except amoxicillin, for which categorization was based on benzylpenicillin results.

**Conclusions:** This work provided a large set of antimicrobial susceptibility data for *C. diphtheriae* and *C. ulcerans*, using a harmonized methodology. The dataset allowed EUCAST and experts in the diphtheria field to develop evidence-based breakpoints in January 2023.

**Introduction**

Diphtheria was a major scourge of humanity until the large-scale roll-out of vaccination.<fnref n="1" /> *Corynebacterium diphtheriae*, the classical agent of diphtheria, is highly transmissible among humans and causes outbreaks of potentially fatal respiratory disease. Cutaneous infections are endemic mainly in tropical areas, but also occasionally in underprivileged populations in other

regions.²⁻⁴ *Corynebacterium ulcerans* is a zoonotic agent of diphtheria that is most often transmitted from household cats and dogs, and can cause infections similar to classical diphtheria, with the important difference that it is not transmissible among humans.⁵

Classical diphtheria, caused by toxigenic *C. diphtheriae*, is currently re-emerging in multiple world regions. Large outbreaks are currently ongoing or have been recently observed, e.g. in Yemen,

<footnote n="1">¹National Consiliary Laboratory for Diphtheria, Bavarian Food and Health Authority (LGL), Oberschleissheim, Germany; ²Institut Pasteur, Université Paris Cité, Biodiversity and Epidemiology of Bacterial Pathogens, 25-28 rue du Docteur Roux, F-75724, Paris, France; ³Institut Pasteur, National Reference Center for Corynebacteria of the Diphtheriae Complex, Paris, France; ⁴EUCAST Development Laboratory (EDL), Växjö, Sweden</footnote>

<footnote>*Corresponding author. E-mail: sylvain.brisse@pasteur.fr</footnote>

<footnote>X @sylvainbrisse</footnote>

<footnote>†These authors contributed equally.</footnote>

<footnote>‡G.K., A.S. and S.B. co-supervised the work.</footnote>
Bangladesh, Nigeria and Guinea.⁶⁻⁸ In Europe, an outbreak of diphtheria among populations of migrants was reported in 2022.³,⁴,⁹ In addition, non-toxigenic isolates of *C. diphtheriae* can cause invasive infections and are often recovered from cutaneous infections, while *C. ulcerans* has been increasingly reported in some Western countries in recent years.⁵,¹⁰,¹¹

Other phylogenetically related corynebacterial species are medically less prominent. The zoonotic species *Corynebacterium pseudotuberculosis* causes a distinct disease (lymphadenitis) and is mainly transmitted from sheep and goats.¹² Although belonging to the potentially toxigenic species, *C. pseudotuberculosis* is extremely rare in humans and nearly always non-toxigenic. Isolates of *Corynebacterium rouxii* and *Corynebacterium belfantii* are, so far, always tox negative.¹³,¹⁴ *Corynebacterium silvaticum* isolates, so far, have all been reported as non-toxigenic toxin-gene bearing (NTTB), while the rarely isolated *Corynebacterium ramonii* can be tox positive or tox negative.¹⁵,¹⁶ The four latter species were recently described and are much more rarely encountered than *C. diphtheriae* and *C. ulcerans*. For practical reasons, and because they form a unique phylogenetic branch within the diversity of corynebacteria, the seven above species are grouped into the *C. diphtheriae* species complex (CdSC).

Although vaccination is the most effective approach to control diphtheria, coverage rates are nowadays insufficient in multiple countries or settings.¹ For clinical cases, diphtheria antitoxin (DAT) is the most important treatment, which must be promptly administered to limit the effects of the diphtheria toxin, but DAT does not limit transmission of the infecting agent, and stockpiles are limited, causing procurement issues. Antimicrobial therapy is therefore critical for clinical care, for reducing transmission and for prophylactic treatment. Benzylpenicillin and erythromycin are the recommended first-line agent treatment options in diphtheria guidelines.

However, there are no consensual antimicrobial susceptibility testing (AST) methods and interpretations for the agents of diphtheria. First, there has been a lack of erythromycin breakpoints. Second, CLSI published the first standardized recommendations for antibiotic susceptibility testing of *Corynebacterium* spp. (including *C. diphtheriae*) in 2006, but its proposed penicillin-susceptible breakpoint was changed in 2015.¹⁷ Third, EUCAST published its first *Corynebacterium* spp. (except *C. diphtheriae*) recommendations in 2014 (EUCAST Breakpoint Tables, version 4.0; https://www.eucast.org/clinical_breakpoints) and updated them by including *C. diphtheriae* in 2016 (version 6.0). In 2019 (version 9.0), *C. diphtheriae* was excluded again from *Corynebacterium* breakpoints. Fourth, interpretations are based on data from other clinically relevant *Corynebacterium* spp. with higher resistance rates, for example *Corynebacterium jeikeium*. This somewhat confusing situation has been maintained until now, in part due to the lack of large series of data from epidemiologically representative isolates, using a harmonized and controlled methodology. Recently, Marosevic et al.¹⁸ analysed a large series of *C. diphtheriae* and *C. ulcerans* isolates for MIC of 12 antimicrobial agents and proposed tentative epidemiological cut-off values, but unfortunately, the erythromycin distribution was truncated.

Here, we aimed to generate data that would enable definition of diphtheria breakpoints using recent clinical isolates. We focused on generating MIC and zone diameter (ZD) distributions

for *C. diphtheriae* and *C. ulcerans*, the two aetiological agents of diphtheria, and used clinical isolates from two European reference laboratories in two countries. Both centres had accumulated large isolate collections with AST data, enabling us to pick isolates representative of a range of MIC values for each antimicrobial class. A standardized methodology was assessed and validated based on well-established EUCAST guidelines and processes. The generated data were shared with the EUCAST Steering Committee and subjected to public consultation, leading to proposed and eventually accepted breakpoints that could be included in the EUCAST Breakpoint Tables v. 13.0, January 2023.

# Materials and methods

## Set-up of a harmonized methodology

To define a single methodology and to control for the quality of materials and procedures, a pilot study organized by the EUCAST Development Laboratory (EDL) aimed to introduce EUCAST methodology and quality requirements in both reference laboratories (France and Germany). Several practice and calibration runs were performed. A collection of *Corynebacterium* spp., comprising *C. diphtheriae*, *C. pseudodiphtheriticum*, *C. striatum* and *C. ulcerans* isolates, carefully selected for representativeness of technical challenges in growth and reading, and with reproducible reference broth microdilution (BMD) results (MIC, mg/L) and disc diffusion results (ZD), was created and distributed from the EDL to the two reference laboratories, together with BMD panels, Mueller-Hinton Fastidious (MH-F) broth and antimicrobial discs. MH-F plates were procured by each laboratory. Testing at the trial sites was blinded. Results were analysed by the EDL and feedback provided to the two participant laboratories. Testing was continued until results, both for MICs and disc diffusion, agreed across the three laboratories. *Streptococcus pneumoniae* ATCC 49619 was included at each test occasion as quality control (QC).

## C. diphtheriae and C. ulcerans isolates

A total of 400 clinical isolates, 100 isolates each of *C. diphtheriae* and *C. ulcerans* for each site, were included. Toxigenic (*tox⁺*) and non-toxigenic (*tox⁻*) strains, with and without previously reported resistance to any of the agents in the study, were included. The ones with previous AST data were chosen to represent a wide range of MIC or ZD values. In France, the clinical *C. diphtheriae* isolates (62 *tox⁻*; 38 *tox⁺*) were collected from humans (n=99; for 1 isolate the origin was unknown), over the years 1951–2017, and the included *C. ulcerans* clinical isolates (50 *tox⁻*; 50 *tox⁺*) were collected from humans (n=60) and animals (n = 40; 18 cats; 20 dogs; 1 horse; 1 rat) over the years 2015–20. In Germany, the included clinical *C. diphtheriae* isolates (54 *tox⁻*; 46 *tox⁺*) were collected from humans (n=96) and animals (n=4) over the years 2010–21, and the included *C. ulcerans* clinical isolates (39 *tox⁻*; 61 *tox⁺*) were collected from humans (n=74) and animals (n=26; 5 cats; 8 dogs) over the years 2010–21. For QC, *S. pneumoniae* ATCC 49619 was used both for disc diffusion and MIC determination.

## AST

Both laboratories used the same lots of BMD panels (Sensititre, Thermo Scientific, UK, custom-made), MH-F broth (in-house produced from BD Difco broth) and antimicrobial discs (Thermo Fisher Scientific, Basingstoke, UK). Local MH-F medium was used for disc diffusion: in France, in-house-produced BD Difco MH-F plates (circular 90 mm); in Germany, commercial pre-poured bioMérieux MH-F plates (square 120×120 mm). Disc diffusion was performed according to EUCAST
Bangladesh, Nigeria and Guinea.⁶⁻⁸ In Europe, an outbreak of diphtheria among populations of migrants was reported in 2022.³,⁴,⁹ In addition, non-toxigenic isolates of *C. diphtheriae* can cause invasive infections and are often recovered from cutaneous infections, while *C. ulcerans* has been increasingly reported in some Western countries in recent years.⁵,¹⁰,¹¹

Other phylogenetically related corynebacterial species are medically less prominent. The zoonotic species *Corynebacterium pseudotuberculosis* causes a distinct disease (lymphadenitis) and is mainly transmitted from sheep and goats.¹² Although belonging to the potentially toxigenic species, *C. pseudotuberculosis* is extremely rare in humans and nearly always non-toxigenic. Isolates of *Corynebacterium rouxii* and *Corynebacterium belfantii* are, so far, always *tox* negative.¹³,¹⁴ *Corynebacterium silvaticum* isolates, so far, have all been reported as non-toxigenic toxin-gene bearing (NTTB), while the rarely isolated *Corynebacterium ramonii* can be *tox* positive or *tox* negative.¹⁵,¹⁶ The four latter species were recently described and are much more rarely encountered than *C. diphtheriae* and *C. ulcerans*. For practical reasons, and because they form a unique phylogenetic branch within the diversity of corynebacteria, the seven above species are grouped into the *C. diphtheriae* species complex (CdSC).

Although vaccination is the most effective approach to control diphtheria, coverage rates are nowadays insufficient in multiple countries or settings.¹ For clinical cases, diphtheria antitoxin (DAT) is the most important treatment, which must be promptly administered to limit the effects of the diphtheria toxin, but DAT does not limit transmission of the infecting agent, and stockpiles are limited, causing procurement issues. Antimicrobial therapy is therefore critical for clinical care, for reducing transmission and for prophylactic treatment. Benzylpenicillin and erythromycin are the recommended first-line agent treatment options in diphtheria guidelines.

However, there are no consensual antimicrobial susceptibility testing (AST) methods and interpretations for the agents of diphtheria. First, there has been a lack of erythromycin breakpoints. Second, CLSI published the first standardized recommendations for antibiotic susceptibility testing of *Corynebacterium* spp. (including *C. diphtheriae*) in 2006, but its proposed penicillin-susceptible breakpoint was changed in 2015.¹⁷ Third, EUCAST published its first *Corynebacterium* spp. (except *C. diphtheriae*) recommendations in 2014 (EUCAST Breakpoint Tables, version 4.0; https://www.eucast.org/clinical_breakpoints) and updated them by including *C. diphtheriae* in 2016 (version 6.0). In 2019 (version 9.0), *C. diphtheriae* was excluded again from *Corynebacterium* breakpoints. Fourth, interpretations are based on data from other clinically relevant *Corynebacterium* spp. with higher resistance rates, for example *Corynebacterium jeikeium*. This somewhat confusing situation has been maintained until now, in part due to the lack of large series of data from epidemiologically representative isolates, using a harmonized and controlled methodology. Recently, Marosevic et al.¹⁸ analysed a large series of *C. diphtheriae* and *C. ulcerans* isolates for MIC of 12 antimicrobial agents and proposed tentative epidemiological cut-off values, but unfortunately, the erythromycin distribution was truncated.

Here, we aimed to generate data that would enable definition of diphtheria breakpoints using recent clinical isolates. We focused on generating MIC and zone diameter (ZD) distributions

for *C. diphtheriae* and *C. ulcerans*, the two aetiological agents of diphtheria, and used clinical isolates from two European reference laboratories in two countries. Both centres had accumulated large isolate collections with AST data, enabling us to pick isolates representative of a range of MIC values for each antimicrobial class. A standardized methodology was assessed and validated based on well-established EUCAST guidelines and processes. The generated data were shared with the EUCAST Steering Committee and subjected to public consultation, leading to proposed and eventually accepted breakpoints that could be included in the EUCAST Breakpoint Tables v. 13.0, January 2023.

## Materials and methods

### Set-up of a harmonized methodology

To define a single methodology and to control for the quality of materials and procedures, a pilot study organized by the EUCAST Development Laboratory (EDL) aimed to introduce EUCAST methodology and quality requirements in both reference laboratories (France and Germany). Several practice and calibration runs were performed. A collection of *Corynebacterium* spp., comprising *C. diphtheriae*, *C. pseudodiphtheriticum*, *C. striatum* and *C. ulcerans* isolates, carefully selected for representativeness of technical challenges in growth and reading, and with reproducible reference broth microdilution (BMD) results (MIC, mg/L) and disc diffusion results (ZD), was created and distributed from the EDL to the two reference laboratories, together with BMD panels, Mueller-Hinton Fastidious (MH-F) broth and antimicrobial discs. MH-F plates were procured by each laboratory. Testing at the trial sites was blinded. Results were analysed by the EDL and feedback provided to the two participant laboratories. Testing was continued until results, both for MICs and disc diffusion, agreed across the three laboratories. *Streptococcus pneumoniae* ATCC 49619 was included at each test occasion as quality control (QC).

### C. diphtheriae and C. ulcerans isolates

A total of 400 clinical isolates, 100 isolates each of *C. diphtheriae* and *C. ulcerans* for each site, were included. Toxigenic (*tox*+) and non-toxigenic (*tox*−) strains, with and without previously reported resistance to any of the agents in the study, were included. The ones with previous AST data were chosen to represent a wide range of MIC or ZD values. In France, the clinical *C. diphtheriae* isolates (62 *tox*−; 38 *tox*+) were collected from humans (n=99; for 1 isolate the origin was unknown), over the years 1951–2017, and the included *C. ulcerans* clinical isolates (50 *tox*−; 50 *tox*+) were collected from humans (n=60) and animals (n = 40; 18 cats; 20 dogs; 1 horse; 1 rat) over the years 2015–20. In Germany, the included clinical *C. diphtheriae* isolates (54 *tox*−; 46 *tox*) were collected from humans (n=96) and animals (n=4) over the years 2010–21, and the included *C. ulcerans* clinical isolates (39 *tox*−; 61 *tox*) were collected from humans (n=74) and animals (n=26; 5 cats; 8 dogs) over the years 2010–21. For QC, *S. pneumoniae* ATCC 49619 was used both for disc diffusion and MIC determination.

### AST

Both laboratories used the same lots of BMD panels (Sensititre, Thermo Scientific, UK, custom-made), MH-F broth (in-house produced from BD Difco broth) and antimicrobial discs (Thermo Fisher Scientific, Basingstoke, UK). Local MH-F medium was used for disc diffusion: in France, in-house-produced BD Difco MH-F plates (circular 90 mm); in Germany, commercial pre-poured bioMérieux MH-F plates (square 120×120 mm). Disc diffusion was performed according to EUCAST
methodology for fastidious organisms, identical to the method recommended for other species of corynebacteria.¹⁹ BMD (MIC; mg/L) was performed according to ISO 20776-1 using MH-F broth. BMD and disc diffusion were performed in parallel using the same inoculum suspension. A few *C. diphtheriae* isolates (n=12) with cefotaxime BMD MICs above the highest concentration on the panel (2 mg/L) were retested with cefotaxime gradient strips (ETEST, bioMérieux, Marcy-l'Étoile, France).

Antibiotic concentration ranges in MIC panels, and disc content, are shown in Table 1. The antimicrobial agents included in the study were agreed with the EUCAST Steering Committee. For benzylpenicillin, the disc content (potency) of 1 IU was used.

## Data analysis

MIC distributions and MIC versus ZD correlation graphs were generated for each antimicrobial agent for *C. diphtheriae* and *C. ulcerans* separately. The MIC versus ZD correlation graphs were analysed visually to ensure that (i) the putative WT isolates formed a Gaussian-shaped normal distribution and (ii) populations with and without resistance mechanisms clearly distinguishable by MIC were also clearly distinguishable by inhibition ZD. The MIC distributions were presented to the EUCAST Steering Committee and were used, together with other relevant information, to establish clinical MIC breakpoints. ZD breakpoints, corresponding to the EUCAST clinical MIC breakpoints, were established with the aim to avoid reporting isolates as falsely susceptible. The numbers of false-susceptible and false-resistant results for the disc diffusion method were calculated for each species-agent combination.

## Results

### QC

QC testing was performed with *S. pneumoniae* ATCC 49619. The results showed that 95.6% (241/252) and 98.0% (294/300) of MICs and 92.7% (191/206) and 96.5% (251/260) of disc diffusion results were within the QC ranges at the German and French laboratories, respectively. MIC and inhibition ZD distributions for the QC strain per site are presented in Table S1(a and b) (available as Supplementary data at JAC Online).

#### MIC distributions

The distributions of MIC values obtained per test site for each species-agent combination are presented in Figure 1 for benzylpenicillin, erythromycin and tetracycline, and in Figure S1 for all agents. The distributions of MIC values based on aggregated data from the two reference laboratories are summarized in Tables 2 and 3 for *C. diphtheriae* and *C. ulcerans*, respectively.

The data were highly consistent between the two laboratories, implying that the populations of isolates included from both countries had closely similar MIC ranges and distributions (Figure S1). Median MIC values for the WT distributions were identical between the two laboratories, except for *C. ulcerans* with doxycycline, for which the median was one dilution higher in the French laboratory (Figure S1p). It was notable that clindamycin was inherently less active against *C. ulcerans* (Figure S1n), whereas the other agents had very comparable WT MIC distributions for the two species.

The following distributions appeared unimodal, hence with an absence of apparent acquired-resistance isolates: linezolid for *C. diphtheriae*; linezolid, benzylpenicillin, amoxicillin, cefotaxime, rifampicin and trimethoprim/sulfamethoxazole for *C. ulcerans*.

## Correlation between MICs and ZD values

We next analysed the correlation between MICs and ZDs for each species-agent combination, based on aggregated data from both sites. MIC versus ZD distributions were produced for each species, as shown for benzylpenicillin, erythromycin and tetracycline in Figure 2 and for all tested agents in Figure S2.

The concordance between MIC and ZD values was excellent for all agents tested. Isolates categorized as susceptible (S), or 'susceptible, increased exposure' (I) where no S category exists, were separated by ZD values, from isolates categorized as resistant (R) with the clinical MIC breakpoints. ZD breakpoints were proposed by visual examination of the MIC-ZD correlation graphs (see, for example, Figure 2), considering the aim to avoid reporting isolates as falsely susceptible. Error rates for the proposed ZD breakpoints versus BMD MICs were low (Table 4).

## Inferred susceptibility to other β-lactams from benzylpenicillin

The correlation between the benzylpenicillin 1 IU disc and MIC values for other β-lactam agents for *C. diphtheriae* and *C. ulcerans* was investigated (Figure S3). Disc diffusion with the benzylpenicillin 1 IU disc (ZD breakpoint R<12 mm) was able to detect all isolates with non-WT MICs to benzylpenicillin, amoxicillin, cefotaxime and meropenem (Figure S3).

## Discussion

The datasets previously used to suggest breakpoints for corynebacteria were either incomplete, because of truncated concentration series, or did not include the two most important species that cause diphtheria. Hence, the agents used for

<table><caption>**Table 1.** Antimicrobial agents, disc potencies and MIC ranges for BMD panels</caption><thead><tr><th>Antimicrobial agent</th><th>Disc content (potency) (µg)</th><th>MIC range on Sensititre BMD panel (mg/L)</th></tr></thead><tbody><tr><td>Benzylpenicillin</td><td>1 IU</td><td>0.016-2</td></tr><tr><td>Ampicillin</td><td>2</td><td>NA</td></tr><tr><td>Amoxicillin</td><td>NT</td><td>0.016-2</td></tr><tr><td>Cefotaxime</td><td>5</td><td>0.016-2</td></tr><tr><td>Meropenem</td><td>10</td><td>0.016-2</td></tr><tr><td>Ciprofloxacin</td><td>5</td><td>0.03-4</td></tr><tr><td>Erythromycin</td><td>15</td><td>0.008-2</td></tr><tr><td>Clindamycin</td><td>2</td><td>0.03-8</td></tr><tr><td>Doxycycline</td><td>NT</td><td>0.03-2</td></tr><tr><td>Tetracycline</td><td>30</td><td>0.06-4</td></tr><tr><td>Linezolid</td><td>10</td><td>0.06-4</td></tr><tr><td>Rifampicin</td><td>5</td><td>0.008-2</td></tr><tr><td>Trimethoprim/ sulfamethoxazole</td><td>1.25-23.75</td><td>0.125-8</td></tr></tbody></table>

NT, not tested (discs for amoxicillin and doxycycline are not part of the EUCAST disc diffusion testing methods for other organisms); NA, not available.
methodology for fastidious organisms, identical to the method recommended for other species of corynebacteria.¹⁹ BMD (MIC; mg/L) was performed according to ISO 20776-1 using MH-F broth. BMD and disc diffusion were performed in parallel using the same inoculum suspension. A few *C. diphtheriae* isolates (n=12) with cefotaxime BMD MICs above the highest concentration on the panel (2 mg/L) were retested with cefotaxime gradient strips (ETEST, bioMérieux, Marcy-l'Étoile, France).

Antibiotic concentration ranges in MIC panels, and disc content, are shown in Table 1. The antimicrobial agents included in the study were agreed with the EUCAST Steering Committee. For benzylpenicillin, the disc content (potency) of 1 IU was used.

## Data analysis

MIC distributions and MIC versus ZD correlation graphs were generated for each antimicrobial agent for *C. diphtheriae* and *C. ulcerans* separately. The MIC versus ZD correlation graphs were analysed visually to ensure that (i) the putative WT isolates formed a Gaussian-shaped normal distribution and (ii) populations with and without resistance mechanisms clearly distinguishable by MIC were also clearly distinguishable by inhibition ZD. The MIC distributions were presented to the EUCAST Steering Committee and were used, together with other relevant information, to establish clinical MIC breakpoints. ZD breakpoints, corresponding to the EUCAST clinical MIC breakpoints, were established with the aim to avoid reporting isolates as falsely susceptible. The numbers of false-susceptible and false-resistant results for the disc diffusion method were calculated for each species-agent combination.

## Results

### QC

QC testing was performed with *S. pneumoniae* ATCC 49619. The results showed that 95.6% (241/252) and 98.0% (294/300) of MICs and 92.7% (191/206) and 96.5% (251/260) of disc diffusion results were within the QC ranges at the German and French laboratories, respectively. MIC and inhibition ZD distributions for the QC strain per site are presented in Table S1(a and b) (available as Supplementary data at JAC Online).

#### MIC distributions

The distributions of MIC values obtained per test site for each species-agent combination are presented in Figure 1 for benzylpenicillin, erythromycin and tetracycline, and in Figure S1 for all agents. The distributions of MIC values based on aggregated data from the two reference laboratories are summarized in Tables 2 and 3 for *C. diphtheriae* and *C. ulcerans*, respectively.

The data were highly consistent between the two laboratories, implying that the populations of isolates included from both countries had closely similar MIC ranges and distributions (Figure S1). Median MIC values for the WT distributions were identical between the two laboratories, except for *C. ulcerans* with doxycycline, for which the median was one dilution higher in the French laboratory (Figure S1p). It was notable that clindamycin was inherently less active against *C. ulcerans* (Figure S1n), whereas the other agents had very comparable WT MIC distributions for the two species.

The following distributions appeared unimodal, hence with an absence of apparent acquired-resistance isolates: linezolid for *C. diphtheriae*; linezolid, benzylpenicillin, amoxicillin, cefotaxime, rifampicin and trimethoprim/sulfamethoxazole for *C. ulcerans*.

## Correlation between MICs and ZD values

We next analysed the correlation between MICs and ZDs for each species-agent combination, based on aggregated data from both sites. MIC versus ZD distributions were produced for each species, as shown for benzylpenicillin, erythromycin and tetracycline in Figure 2 and for all tested agents in Figure S2.

The concordance between MIC and ZD values was excellent for all agents tested. Isolates categorized as susceptible (S), or 'susceptible, increased exposure' (I) where no S category exists, were separated by ZD values, from isolates categorized as resistant (R) with the clinical MIC breakpoints. ZD breakpoints were proposed by visual examination of the MIC-ZD correlation graphs (see, for example, Figure 2), considering the aim to avoid reporting isolates as falsely susceptible. Error rates for the proposed ZD breakpoints versus BMD MICs were low (Table 4).

## Inferred susceptibility to other β-lactams from benzylpenicillin

The correlation between the benzylpenicillin 1 IU disc and MIC values for other β-lactam agents for *C. diphtheriae* and *C. ulcerans* was investigated (Figure S3). Disc diffusion with the benzylpenicillin 1 IU disc (ZD breakpoint R<12 mm) was able to detect all isolates with non-WT MICs to benzylpenicillin, amoxicillin, cefotaxime and meropenem (Figure S3).

## Discussion

The datasets previously used to suggest breakpoints for Corynebacteria were either incomplete, because of truncated concentration series, or did not include the two most important species that cause diphtheria. Hence, the agents used for

<table><caption>**Table 1.** Antimicrobial agents, disc potencies and MIC ranges for BMD panels</caption><thead><tr><th>Antimicrobial agent</th><th>Disc content (potency) (µg)</th><th>MIC range on Sensititre BMD panel (mg/L)</th></tr></thead><tbody><tr><td>Benzylpenicillin</td><td>1 IU</td><td>0.016-2</td></tr><tr><td>Ampicillin</td><td>2</td><td>NA</td></tr><tr><td>Amoxicillin</td><td>NT</td><td>0.016-2</td></tr><tr><td>Cefotaxime</td><td>5</td><td>0.016-2</td></tr><tr><td>Meropenem</td><td>10</td><td>0.016-2</td></tr><tr><td>Ciprofloxacin</td><td>5</td><td>0.03-4</td></tr><tr><td>Erythromycin</td><td>15</td><td>0.008-2</td></tr><tr><td>Clindamycin</td><td>2</td><td>0.03-8</td></tr><tr><td>Doxycycline</td><td>NT</td><td>0.03-2</td></tr><tr><td>Tetracycline</td><td>30</td><td>0.06-4</td></tr><tr><td>Linezolid</td><td>10</td><td>0.06-4</td></tr><tr><td>Rifampicin</td><td>5</td><td>0.008-2</td></tr><tr><td>Trimethoprim/ sulfamethoxazole</td><td>1.25-23.75</td><td>0.125-8</td></tr></tbody></table>

NT, not tested (discs for amoxicillin and doxycycline are not part of the EUCAST disc diffusion testing methods for other organisms); NA, not available.
<figure><img src="image_2.png" /><figcaption>**Figure 1.** MIC distributions per test site for benzylpenicillin, erythromycin and tetracycline for *C. diphtheriae* isolates (to the left) and *C. ulcerans* isolates (to the right). DE = Germany (blue bars), FR = France (red bars). EUCAST MIC breakpoints (EUCAST Breakpoint Tables v. 13.1) are shown as dotted lines (I/R for benzylpenicillin, S/R for erythromycin and tetracycline).</figcaption></figure>

diphtheria were excluded from the EUCAST breakpoint tables (Breakpoint Tables v. 4.0, 2014). In recent attempts to provide epidemiological cut-offs,¹⁸,²⁰ the methodology used was not generally accepted. Therefore, evidence-based breakpoints of *C. diphtheriae* and *C. ulcerans* have been missing. In addition, breakpoints for benzylpenicillin have been under discussion.¹⁷ The lack of agreed methodology and breakpoints has confused knowledge on the prevalence and geographical distribution of resistance to antimicrobial agents. Indeed, it is difficult to interpret most previous studies reporting resistance, given the uncontrolled methodology and because the raw MIC or ZD values are typically not provided. This confusion is illustrated by highly inconsistent reports on benzylpenicillin susceptibility, with some studies reporting most or all isolates as resistant,²¹ whereas other studies report very few resistant

isolates.¹⁸,²⁰ Here, we aimed to generate data that would enable definition of breakpoints for *C. diphtheriae* and *C. ulcerans*, using at the same time, large representative datasets generated from recent clinical isolates, and a standardized methodology. The resurgence of diphtheria in low- and middle-income countries (LMICs) (mostly due to *C. diphtheriae*) and in Western countries (often caused also by *C. ulcerans*), underlines the timeliness of defining breakpoints based on firm evidence.

A pilot study was conducted to ensure reproducibility and comparability of the generated MIC and ZD values across three laboratories. Controlling for agar depth, inoculation quantities and methods, and drying of MH-F plates were shown to be important to reach comparability, and were adjusted accordingly in the harmonized procedure.
<figure><img src="image_2.png" /><figcaption>**Figure 1.** MIC distributions per test site for benzylpenicillin, erythromycin and tetracycline for *C. diphtheriae* isolates (to the left) and *C. ulcerans* isolates (to the right). DE = Germany (blue bars), FR = France (red bars). EUCAST MIC breakpoints (EUCAST Breakpoint Tables v. 13.1) are shown as dotted lines (I/R for benzylpenicillin, S/R for erythromycin and tetracycline).</figcaption></figure>

diphtheria were excluded from the EUCAST breakpoint tables (Breakpoint Tables v. 4.0, 2014). In recent attempts to provide epidemiological cut-offs,¹⁸,²⁰ the methodology used was not generally accepted. Therefore, evidence-based breakpoints of *C. diphtheriae* and *C. ulcerans* have been missing. In addition, breakpoints for benzylpenicillin have been under discussion.¹⁷ The lack of agreed methodology and breakpoints has confused knowledge on the prevalence and geographical distribution of resistance to antimicrobial agents. Indeed, it is difficult to interpret most previous studies reporting resistance, given the uncontrolled methodology and because the raw MIC or ZD values are typically not provided. This confusion is illustrated by highly inconsistent reports on benzylpenicillin susceptibility, with some studies reporting most or all isolates as resistant,²¹ whereas other studies report very few resistant

isolates.¹⁸,²⁰ Here, we aimed to generate data that would enable definition of breakpoints for *C. diphtheriae* and *C. ulcerans*, using at the same time, large representative datasets generated from recent clinical isolates, and a standardized methodology. The resurgence of diphtheria in low- and middle-income countries (LMICs) (mostly due to *C. diphtheriae*) and in Western countries (often caused also by *C. ulcerans*), underlines the timeliness of defining breakpoints based on firm evidence.

A pilot study was conducted to ensure reproducibility and comparability of the generated MIC and ZD values across three laboratories. Controlling for agar depth, inoculation quantities and methods, and drying of MH-F plates were shown to be important to reach comparability, and were adjusted accordingly in the harmonized procedure.
<table><caption>**Table 2.** MIC distributions (mg/L) for *C. diphtheriae* (n=200) based on aggregated data from testing at two laboratories (100 isolates each)</caption><thead><tr><th>Antimicrobial agent</th><th>0.008</th><th>0.016</th><th>0.03</th><th>0.06</th><th>0.125</th><th>0.25</th><th>0.5</th><th>1</th><th>2</th><th>4</th><th>8</th><th>16</th></tr></thead><tbody><tr><td>Benzylpenicillin</td><td></td><td></td><td>1</td><td>4</td><td>27</td><td>124</td><td>29</td><td>5</td><td><strong>7</strong></td><td><strong>3</strong></td><td></td><td></td></tr><tr><td>Amoxicillin</td><td></td><td></td><td>1</td><td>2</td><td>15</td><td>116</td><td>53</td><td>7</td><td><strong>3</strong></td><td><strong>3</strong></td><td></td><td></td></tr><tr><td>Cefotaxime</td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td><td>31</td><td>166</td><td>2</td><td></td><td></td></tr><tr><td>Meropenem</td><td></td><td>3</td><td>23</td><td>144</td><td>21</td><td>8</td><td></td><td><strong>1</strong></td><td></td><td></td><td></td><td></td></tr><tr><td>Ciprofloxacin</td><td></td><td></td><td>6</td><td>152</td><td>22</td><td>4</td><td>9</td><td><strong>3</strong></td><td><strong>1</strong></td><td><strong>1</strong></td><td><strong>2</strong></td><td></td></tr><tr><td>Erythromycin</td><td>158</td><td>26</td><td>5</td><td></td><td><strong>2</strong></td><td><strong>1</strong></td><td><strong>2</strong></td><td></td><td><strong>1</strong></td><td><strong>4</strong></td><td></td><td></td></tr><tr><td>Clindamycin</td><td></td><td></td><td>4</td><td>34</td><td>135</td><td>20</td><td>2</td><td></td><td></td><td></td><td></td><td><strong>5</strong></td></tr><tr><td>Doxycycline</td><td></td><td></td><td></td><td>5</td><td>104</td><td>17</td><td>10</td><td><strong>8</strong></td><td><strong>4</strong></td><td><strong>52</strong></td><td></td><td></td></tr><tr><td>Tetracycline</td><td></td><td></td><td></td><td></td><td>11</td><td>108</td><td>5</td><td>1</td><td></td><td><strong>2</strong></td><td><strong>73</strong></td><td></td></tr><tr><td>Linezolid</td><td></td><td></td><td></td><td></td><td>1</td><td>190</td><td>6</td><td>3</td><td></td><td></td><td></td><td></td></tr><tr><td>Rifampicin</td><td>179</td><td>7</td><td>2</td><td>3</td><td></td><td></td><td></td><td></td><td></td><td><strong>9</strong></td><td></td><td></td></tr><tr><td>Trimethoprim/sulfamethoxazole</td><td></td><td></td><td></td><td></td><td>116</td><td>15</td><td>4</td><td><strong>7</strong></td><td><strong>12</strong></td><td><strong>10</strong></td><td><strong>9</strong></td><td><strong>27</strong></td></tr></tbody></table>

Truncated MIC distributions are indicated by an extremity in italics, and isolates resistant by EUCAST breakpoints are in bold.

<table><caption>**Table 3.** MIC distributions (mg/L) for *C. ulcerans* (n=200) based on aggregated data from testing at two laboratories (100 isolates each)</caption><thead><tr><th>Antimicrobial agent</th><th>0.008</th><th>0.016</th><th>0.03</th><th>0.06</th><th>0.125</th><th>0.25</th><th>0.5</th><th>1</th><th>2</th><th>4</th><th>8</th><th>16</th></tr></thead><tbody><tr><td>Benzylpenicillin</td><td></td><td></td><td></td><td>1</td><td>31</td><td>156</td><td>11</td><td>1</td><td></td><td></td><td></td><td></td></tr><tr><td>Amoxicillin</td><td></td><td></td><td></td><td></td><td>27</td><td>164</td><td>9</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Cefotaxime</td><td></td><td></td><td></td><td></td><td></td><td></td><td>11</td><td>175</td><td>14</td><td></td><td></td><td></td></tr><tr><td>Meropenem</td><td></td><td></td><td>16</td><td>127</td><td>53</td><td>3</td><td><strong>1</strong></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ciprofloxacin</td><td></td><td></td><td>5</td><td>151</td><td>16</td><td>19</td><td>2</td><td><strong>1</strong></td><td><strong>2</strong></td><td><strong>3</strong></td><td><strong>1</strong></td><td></td></tr><tr><td>Erythromycin</td><td>6</td><td>187</td><td>6</td><td></td><td></td><td></td><td></td><td></td><td></td><td><strong>1</strong></td><td></td><td></td></tr><tr><td>Clindamycin</td><td></td><td></td><td></td><td>1</td><td>3</td><td></td><td>10</td><td>78</td><td>106</td><td>1</td><td></td><td>1</td></tr><tr><td>Doxycycline</td><td></td><td></td><td></td><td>1</td><td>121</td><td>72</td><td>3</td><td><strong>2</strong></td><td></td><td><strong>1</strong></td><td></td><td></td></tr><tr><td>Tetracycline</td><td></td><td></td><td></td><td></td><td>3</td><td>174</td><td>16</td><td>2</td><td></td><td><strong>2</strong></td><td><strong>3</strong></td><td></td></tr><tr><td>Linezolid</td><td></td><td></td><td></td><td></td><td></td><td>80</td><td>119</td><td>1</td><td></td><td></td><td></td><td></td></tr><tr><td>Rifampicin</td><td>200</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Trimethoprim/sulfamethoxazole</td><td></td><td></td><td></td><td></td><td>185</td><td>14</td><td>1</td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table>

Truncated MICs distributions are indicated by an extremity in italics, and isolates resistant by EUCAST breakpoints are in bold.

Following the defined EUCAST methodology, we generated distributions of MIC and ZD values using two large and independent sets of clinical isolates from two national surveillance programmes. The distributions were remarkably consistent between countries, providing confidence in the dataset and supporting its use as a basis for breakpoint definitions.

Based on the observed MIC and ZD distributions and correlations, EUCAST proposed clinical MIC breakpoints and disc diffusion correlates for routine susceptibility testing of the 12 agents including benzylpenicillin and erythromycin, the two first-line agents recommended by WHO. The breakpoints proposed by EUCAST were subjected to public consultation, leading to proposed, and eventually accepted, breakpoints, which were included in the EUCAST Breakpoint Tables v. 13.0, 2023. Following the present work, benzylpenicillin breakpoints for the other corynebacteria were changed to $S \le 0.001/R > 1$ mg/L from v. 14.0 of the breakpoint tables (EUCAST Breakpoint Tables v 14.0, preliminary version, 5 December 2023.). A table with an overview of the EUCAST breakpoints and their comparison with CLSI

breakpoints is provided (Table 5). As is evident, there are several major differences, which from an international public health angle would benefit from a discussion with the aim to harmonize between the two committees. It should be noted that CLSI breakpoints are common for all corynebacteria, whereas EUCAST breakpoints for *C. diphtheriae* and *C. ulcerans* are specific for these species and separated from breakpoints for other *Corynebacterium* species.

For species-agent combinations where there is clinical evidence and practice with WT isolates, i.e. isolates lacking any evidence of phenotypically detectable acquired resistance, the general EUCAST principle for setting breakpoints for an agent to a species is to primarily assign a susceptibility category of S or I to WT isolates and to then, depending on clinical evidence, tradition and experience, pharmacokinetic/pharmacodynamic (PK/ PD) data, dosing traditions etc., categorize non-WT isolates with MICs above a defined level as R.

When comparing *C. diphtheriae* and *C. ulcerans*, MIC values showed highly similar distributions, with the notable difference
<table><caption>**Table 2.** MIC distributions (mg/L) for *C. diphtheriae* (n=200) based on aggregated data from testing at two laboratories (100 isolates each)</caption><thead><tr><th>Antimicrobial agent</th><th>0.008</th><th>0.016</th><th>0.03</th><th>0.06</th><th>0.125</th><th>0.25</th><th>0.5</th><th>1</th><th>2</th><th>4</th><th>8</th><th>16</th></tr></thead><tbody><tr><td>Benzylpenicillin</td><td></td><td></td><td>1</td><td>4</td><td>27</td><td>124</td><td>29</td><td>5</td><td><strong>7</strong></td><td><strong>3</strong></td><td></td><td></td></tr><tr><td>Amoxicillin</td><td></td><td></td><td>1</td><td>2</td><td>15</td><td>116</td><td>53</td><td>7</td><td><strong>3</strong></td><td><strong>3</strong></td><td></td><td></td></tr><tr><td>Cefotaxime</td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td><td>31</td><td>166</td><td>2</td><td></td><td></td></tr><tr><td>Meropenem</td><td></td><td>3</td><td>23</td><td>144</td><td>21</td><td>8</td><td></td><td><strong>1</strong></td><td></td><td></td><td></td><td></td></tr><tr><td>Ciprofloxacin</td><td></td><td></td><td>6</td><td>152</td><td>22</td><td>4</td><td>9</td><td><strong>3</strong></td><td><strong>1</strong></td><td><strong>1</strong></td><td><strong>2</strong></td><td></td></tr><tr><td>Erythromycin</td><td>158</td><td>26</td><td>5</td><td></td><td><strong>2</strong></td><td><strong>1</strong></td><td><strong>2</strong></td><td></td><td><strong>1</strong></td><td><strong>4</strong></td><td></td><td></td></tr><tr><td>Clindamycin</td><td></td><td></td><td>4</td><td>34</td><td>135</td><td>20</td><td>2</td><td></td><td></td><td></td><td></td><td><strong>5</strong></td></tr><tr><td>Doxycycline</td><td></td><td></td><td></td><td>5</td><td>104</td><td>17</td><td>10</td><td><strong>8</strong></td><td><strong>4</strong></td><td><strong>52</strong></td><td></td><td></td></tr><tr><td>Tetracycline</td><td></td><td></td><td></td><td></td><td>11</td><td>108</td><td>5</td><td>1</td><td></td><td><strong>2</strong></td><td><strong>73</strong></td><td></td></tr><tr><td>Linezolid</td><td></td><td></td><td></td><td></td><td>1</td><td>190</td><td>6</td><td>3</td><td></td><td></td><td></td><td></td></tr><tr><td>Rifampicin</td><td>179</td><td>7</td><td>2</td><td>3</td><td></td><td></td><td></td><td></td><td></td><td><strong>9</strong></td><td></td><td></td></tr><tr><td>Trimethoprim/sulfamethoxazole</td><td></td><td></td><td></td><td></td><td>116</td><td>15</td><td>4</td><td><strong>7</strong></td><td><strong>12</strong></td><td><strong>10</strong></td><td><strong>9</strong></td><td><strong>27</strong></td></tr></tbody></table>

Truncated MIC distributions are indicated by an extremity in italics, and isolates resistant by EUCAST breakpoints are in bold.

<table><caption>**Table 3.** MIC distributions (mg/L) for *C. ulcerans* (n=200) based on aggregated data from testing at two laboratories (100 isolates each)</caption><thead><tr><th>Antimicrobial agent</th><th>0.008</th><th>0.016</th><th>0.03</th><th>0.06</th><th>0.125</th><th>0.25</th><th>0.5</th><th>1</th><th>2</th><th>4</th><th>8</th><th>16</th></tr></thead><tbody><tr><td>Benzylpenicillin</td><td></td><td></td><td></td><td>1</td><td>31</td><td>156</td><td>11</td><td>1</td><td></td><td></td><td></td><td></td></tr><tr><td>Amoxicillin</td><td></td><td></td><td></td><td></td><td>27</td><td>164</td><td>9</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Cefotaxime</td><td></td><td></td><td></td><td></td><td></td><td></td><td>11</td><td>175</td><td>14</td><td></td><td></td><td></td></tr><tr><td>Meropenem</td><td></td><td></td><td>16</td><td>127</td><td>53</td><td>3</td><td><strong>1</strong></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ciprofloxacin</td><td></td><td></td><td>5</td><td>151</td><td>16</td><td>19</td><td>2</td><td><strong>1</strong></td><td><strong>2</strong></td><td><strong>3</strong></td><td><strong>1</strong></td><td></td></tr><tr><td>Erythromycin</td><td>6</td><td>187</td><td>6</td><td></td><td></td><td></td><td></td><td></td><td></td><td><strong>1</strong></td><td></td><td></td></tr><tr><td>Clindamycin</td><td></td><td></td><td></td><td>1</td><td>3</td><td></td><td>10</td><td>78</td><td>106</td><td>1</td><td></td><td>1</td></tr><tr><td>Doxycycline</td><td></td><td></td><td></td><td>1</td><td>121</td><td>72</td><td>3</td><td><strong>2</strong></td><td></td><td><strong>1</strong></td><td></td><td></td></tr><tr><td>Tetracycline</td><td></td><td></td><td></td><td></td><td>3</td><td>174</td><td>16</td><td>2</td><td></td><td><strong>2</strong></td><td><strong>3</strong></td><td></td></tr><tr><td>Linezolid</td><td></td><td></td><td></td><td></td><td></td><td>80</td><td>119</td><td>1</td><td></td><td></td><td></td><td></td></tr><tr><td>Rifampicin</td><td>200</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Trimethoprim/sulfamethoxazole</td><td></td><td></td><td></td><td></td><td>185</td><td>14</td><td>1</td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table>

Truncated MICs distributions are indicated by an extremity in italics, and isolates resistant by EUCAST breakpoints are in bold.

Following the defined EUCAST methodology, we generated distributions of MIC and ZD values using two large and independent sets of clinical isolates from two national surveillance programmes. The distributions were remarkably consistent between countries, providing confidence in the dataset and supporting its use as a basis for breakpoint definitions.

Based on the observed MIC and ZD distributions and correlations, EUCAST proposed clinical MIC breakpoints and disc diffusion correlates for routine susceptibility testing of the 12 agents including benzylpenicillin and erythromycin, the two first-line agents recommended by WHO. The breakpoints proposed by EUCAST were subjected to public consultation, leading to proposed, and eventually accepted, breakpoints, which were included in the EUCAST Breakpoint Tables v. 13.0, 2023. Following the present work, benzylpenicillin breakpoints for the other corynebacteria were changed to $S \le 0.001/R > 1$ mg/L from v. 14.0 of the breakpoint tables (EUCAST Breakpoint Tables v 14.0, preliminary version, 5 December 2023.). A table with an overview of the EUCAST breakpoints and their comparison with CLSI

breakpoints is provided (Table 5). As is evident, there are several major differences, which from an international public health angle would benefit from a discussion with the aim to harmonize between the two committees. It should be noted that CLSI breakpoints are common for all corynebacteria, whereas EUCAST breakpoints for *C. diphtheriae* and *C. ulcerans* are specific for these species and separated from breakpoints for other *Corynebacterium* species.

For species-agent combinations where there is clinical evidence and practice with WT isolates, i.e. isolates lacking any evidence of phenotypically detectable acquired resistance, the general EUCAST principle for setting breakpoints for an agent to a species is to primarily assign a susceptibility category of S or I to WT isolates and to then, depending on clinical evidence, tradition and experience, pharmacokinetic/pharmacodynamic (PK/ PD) data, dosing traditions etc., categorize non-WT isolates with MICs above a defined level as R.

When comparing *C. diphtheriae* and *C. ulcerans*, MIC values showed highly similar distributions, with the notable difference
<figure><img src="image_3.png" /></figure>

<figure><img src="image_4.png" /></figure>

<figure><img src="image_5.png" /></figure>

<figure><img src="image_6.png" /></figure>

<figure><img src="image_7.png" /></figure>

<figure><img src="image_8.png" /><figcaption>**Figure 2.** Inhibition ZD distributions for benzylpenicillin, erythromycin and tetracycline for *C. diphtheriae* isolates (to the left) and *C. ulcerans* isolates (to the right), showing aggregated data from two laboratories (n = 100 isolates per species per site). Corresponding MIC values on Sensititre panels are shown as coloured bars according to EUCAST MIC breakpoints: susceptible (S) = green, susceptible, increased exposure (I) = yellow and resistant (R) = orange/red. EUCAST zone diameter breakpoints are indicated by dotted lines (I/R for benzylpenicillin, S/R for erythromycin and tetracycline).</figcaption></figure>

of clindamycin, which was inherently less active to *C. ulcerans*, as previously reported.¹⁸ Hence, no clindamycin breakpoint was proposed for *C. ulcerans*. The mechanism by which most *C. ulcerans* are resistant to clindamycin deserves further investigation. For other agents, although the WT distribution was almost identical, the *C. diphtheriae* dataset included more isolates with acquired resistance, most notably to benzylpenicillin, erythromycin, tetracycline and trimethoprim/sulfamethoxazole (Figures 1 and 2, Figures S1 and S2). This was consistent with our choice to include isolates with acquired resistance mechanisms that were previously described in this species, including *pbp2m*, *erm(X)*, *tet(33)*, *tet(O)*, *tet(W)* and *sul1*.²²

The precision of disc diffusion and its ability to predict resistance was high, as the observed false-positive and false-negative

results were very low (Table 4). This result is important, as it indicates that the disc diffusion method, which is easier and less expensive than MIC determination, is suitable as a first-line method to define susceptibility. Error rates with ZD values were very low and almost always false resistant (major error; ME) and very rarely false susceptible (very major error; VME). For clinical purposes, in most cases reporting the actual MIC value will rarely be helpful; therefore, susceptibility can be reported as S, I or R, based on the disc diffusion result. In a routine surveillance workflow, in outbreak situations and for research purposes, MIC determination would be needed only for resistant isolates as determined by disc diffusion.

Interestingly, benzylpenicillin susceptibility can be used to predict susceptibility to other (more potent) β-lactam agents.
<figure><img src="image_3.png" /></figure>

<figure><img src="image_4.png" /></figure>

<figure><img src="image_5.png" /></figure>

<figure><img src="image_6.png" /></figure>

<figure><img src="image_7.png" /></figure>

<figure><img src="image_8.png" /><figcaption>**Figure 2.** Inhibition ZD distributions for benzylpenicillin, erythromycin and tetracycline for *C. diphtheriae* isolates (to the left) and *C. ulcerans* isolates (to the right), showing aggregated data from two laboratories (n = 100 isolates per species per site). Corresponding MIC values on Sensititre panels are shown as coloured bars according to EUCAST MIC breakpoints: susceptible (S) = green, susceptible, increased exposure (I) = yellow and resistant (R) = orange/red. EUCAST zone diameter breakpoints are indicated by dotted lines (I/R for benzylpenicillin, S/R for erythromycin and tetracycline).</figcaption></figure>

of clindamycin, which was inherently less active to *C. ulcerans*, as previously reported.¹⁸ Hence, no clindamycin breakpoint was proposed for *C. ulcerans*. The mechanism by which most *C. ulcerans* are resistant to clindamycin deserves further investigation. For other agents, although the WT distribution was almost identical, the *C. diphtheriae* dataset included more isolates with acquired resistance, most notably to benzylpenicillin, erythromycin, tetracycline and trimethoprim/sulfamethoxazole (Figures 1 and 2, Figures S1 and S2). This was consistent with our choice to include isolates with acquired resistance mechanisms that were previously described in this species, including *pbp2m*, *erm(X)*, *tet(33)*, *tet(O)*, *tet(W)* and *sul1*.²²

The precision of disc diffusion and its ability to predict resistance was high, as the observed false-positive and false-negative

results were very low (Table 4). This result is important, as it indicates that the disc diffusion method, which is easier and less expensive than MIC determination, is suitable as a first-line method to define susceptibility. Error rates with ZD values were very low and almost always false resistant (major error; ME) and very rarely false susceptible (very major error; VME). For clinical purposes, in most cases reporting the actual MIC value will rarely be helpful; therefore, susceptibility can be reported as S, I or R, based on the disc diffusion result. In a routine surveillance workflow, in outbreak situations and for research purposes, MIC determination would be needed only for resistant isolates as determined by disc diffusion.

Interestingly, benzylpenicillin susceptibility can be used to predict susceptibility to other (more potent) β-lactam agents.
<table><caption>**Table 4.** Errors observed for proposed ZD breakpoints versus reference BMD MICs</caption><thead><tr><th rowspan="2">Antimicrobial agent</th><th colspan="4">C. diphtheriae (n=200)</th><th colspan="4">C. ulcerans (n=200)</th></tr><tr><th>No. of susceptible<sup>a</sup> isolates</th><th>No. of resistant<sup>b</sup> isolates</th><th>No. of false-susceptible<sup>c</sup> results</th><th>No. of false-resistant<sup>d</sup> results</th><th>No. of susceptible<sup>a</sup> isolates</th><th>No. of resistant<sup>b</sup> isolates</th><th>No. of false-susceptible<sup>c</sup> results</th><th>No. of false-resistant<sup>d</sup> results</th></tr></thead><tbody><tr><td>Benzylpenicillin</td><td>190</td><td>10</td><td>0</td><td>1</td><td>200</td><td>0</td><td>NA</td><td>0</td></tr><tr><td>Cefotaxime</td><td>198</td><td>2</td><td>0</td><td>2</td><td>200</td><td>0</td><td>NA</td><td>0</td></tr><tr><td>Meropenem</td><td>199</td><td>1</td><td>0</td><td>4</td><td>199</td><td>1</td><td>0</td><td>1</td></tr><tr><td>Ciprofloxacin</td><td>193</td><td>7</td><td>1</td><td>4</td><td>193</td><td>7</td><td>0</td><td>7</td></tr><tr><td>Erythromycin</td><td>189</td><td>10</td><td>2</td><td>1</td><td>199</td><td>1</td><td>0</td><td>0</td></tr><tr><td>Clindamycin</td><td>195</td><td>5</td><td>0</td><td>1</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td>Tetracycline</td><td>125</td><td>75</td><td>0</td><td>3</td><td>195</td><td>5</td><td>0</td><td>0</td></tr><tr><td>Linezolid</td><td>200</td><td>0</td><td>NA</td><td>0</td><td>200</td><td>0</td><td>NA</td><td>3</td></tr><tr><td>Rifampicin</td><td>191</td><td>9</td><td>0</td><td>0</td><td>200</td><td>0</td><td>NA</td><td>0</td></tr><tr><td>Trimethoprim/ sulfamethoxazole</td><td>135</td><td>65</td><td>0</td><td>8</td><td>200</td><td>0</td><td>NA</td><td>0</td></tr></tbody></table>

NA, not applicable since no resistant isolates were included.

<sup>a</sup>Categorized as susceptible (S) or susceptible, increased exposure (I) according to MIC.

<sup>b</sup>Categorized as resistant (R) according to MIC.

<sup>c</sup>Susceptible (S) or susceptible, increased exposure (I) with disc diffusion; resistant (R) with BMD.

<sup>d</sup>Resistant (R) with disc diffusion; susceptible (S) or susceptible, increased exposure (I) with BMD.

<table><caption>**Table 5.** Comparison of EUCAST and CLSI MIC breakpoints (mg/L) for *C. diphtheriae* and *C. ulcerans*</caption><thead><tr><th>Antimicrobial agent</th><th>EUCAST MIC<br>breakpoints<sup>a</sup><br>for C. diphtheriae<br>and<br>C. ulcerans<br>(S ≤ /R&gt;)</th><th>CLSI MIC breakpoints<sup>b</sup><br>for Corynebacterium spp.<br>including<br>C. diphtheriae<br>(S ≤ /R&gt;)</th></tr></thead><tbody><tr><td>Benzylpenicillin</td><td>0.001/1</td><td>0.125/2</td></tr><tr><td>Amoxicillin</td><td>1/1</td><td>—</td></tr><tr><td>Cefotaxime</td><td>0.001/2</td><td>1/2</td></tr><tr><td>Meropenem</td><td>0.25/0.25</td><td>0.25/0.5</td></tr><tr><td>Ciprofloxacin</td><td>0.001/0.5</td><td>1/2</td></tr><tr><td>Erythromycin</td><td>0.06/0.06</td><td>0.5/1</td></tr><tr><td>Clindamycin</td><td>0.5/0.5<sup>c</sup></td><td>0.5/2<sup>c</sup></td></tr><tr><td>Doxycycline</td><td>0.5/0.5</td><td>4/8</td></tr><tr><td>Tetracycline</td><td>1/1</td><td>4/8</td></tr><tr><td>Linezolid</td><td>2/2</td><td>2/1</td></tr><tr><td>Rifampicin</td><td>0.06/0.06</td><td>1/2</td></tr><tr><td>Trimethoprim/<br>sulfamethoxazole</td><td>0.5/0.5</td><td>2/2</td></tr></tbody></table>

<sup>a</sup>EUCAST Breakpoint Tables for Interpretation of MICs and Zone Diameters v. 13.1, 2023 and v. 14.0, 2024.

<sup>b</sup>CLSI M45—Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria. Third Edition, 2015. In this table, CLSI breakpoints are expressed in the EUCAST format (S≤, R≥) for comparison.

<sup>c</sup>Breakpoints apply to *C. diphtheriae* only.

This enables a penicillin screening testing strategy; since most isolates will be in the WT distribution for β-lactams, these can, without further testing, be reported as S to amoxicillin and meropenem and/or I to cefotaxime, based on the benzylpenicillin test result. Only the few benzylpenicillin-resistant isolates should then also be tested for other β-lactam agents. Similarly, tetracycline can be used to infer susceptibility to doxycycline.

This study has two limitations. First, the isolate collection comprised isolates from two neighbouring European countries. However, these were large collections of isolates, deduplicated with respect to epidemiological links, and it was shown that the phylogenetic diversity of surveillance isolates from these countries is highly representative of the global diversity of phylogenetic sublineages that circulate elsewhere.²²,²³ However, more geographically representative collections of isolates should be characterized in the future to confirm the WT MIC distributions that were found herein. Second, other species of the CdSC, including *C. pseudotuberculosis*, *C. belfantii*, *C. rouxii* and *C. silvaticum*, were not tested. These species either cause other infections (*C. pseudotuberculosis*), are tox negative (*C. rouxii* and *C. belfantii*) or are rare zoonotic non-toxigenic species (*C. silvaticum*). Given their phylogenetic and biological proximity, it can be expected that the proposed breakpoints for *C. diphtheriae* and *C. ulcerans* may be applied to these species too. However, future studies should test this hypothesis, as there might be exceptions, as illustrated here for clindamycin, which differs in its potency against *C. diphtheriae* and *C. ulcerans*.

Given the critical importance of antimicrobial therapy and prophylaxis in diphtheria clinical care and transmission control, and the increasing reporting of MDR tox-positive *C. diphtheriae* isolates,²²,²⁴,²⁵ the EUCAST breakpoints determined based on
<table><caption>**Table 4.** Errors observed for proposed ZD breakpoints versus reference BMD MICs</caption><thead><tr><th rowspan="2">Antimicrobial agent</th><th colspan="4">C. diphtheriae (n=200)</th><th colspan="4">C. ulcerans (n=200)</th></tr><tr><th>No. of susceptible<sup>a</sup> isolates</th><th>No. of resistant<sup>b</sup> isolates</th><th>No. of false-susceptible<sup>c</sup> results</th><th>No. of false-resistant<sup>d</sup> results</th><th>No. of susceptible<sup>a</sup> isolates</th><th>No. of resistant<sup>b</sup> isolates</th><th>No. of false-susceptible<sup>c</sup> results</th><th>No. of false-resistant<sup>d</sup> results</th></tr></thead><tbody><tr><td>Benzylpenicillin</td><td>190</td><td>10</td><td>0</td><td>1</td><td>200</td><td>0</td><td>NA</td><td>0</td></tr><tr><td>Cefotaxime</td><td>198</td><td>2</td><td>0</td><td>2</td><td>200</td><td>0</td><td>NA</td><td>0</td></tr><tr><td>Meropenem</td><td>199</td><td>1</td><td>0</td><td>4</td><td>199</td><td>1</td><td>0</td><td>1</td></tr><tr><td>Ciprofloxacin</td><td>193</td><td>7</td><td>1</td><td>4</td><td>193</td><td>7</td><td>0</td><td>7</td></tr><tr><td>Erythromycin</td><td>189</td><td>10</td><td>2</td><td>1</td><td>199</td><td>1</td><td>0</td><td>0</td></tr><tr><td>Clindamycin</td><td>195</td><td>5</td><td>0</td><td>1</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td>Tetracycline</td><td>125</td><td>75</td><td>0</td><td>3</td><td>195</td><td>5</td><td>0</td><td>0</td></tr><tr><td>Linezolid</td><td>200</td><td>0</td><td>NA</td><td>0</td><td>200</td><td>0</td><td>NA</td><td>3</td></tr><tr><td>Rifampicin</td><td>191</td><td>9</td><td>0</td><td>0</td><td>200</td><td>0</td><td>NA</td><td>0</td></tr><tr><td>Trimethoprim/ sulfamethoxazole</td><td>135</td><td>65</td><td>0</td><td>8</td><td>200</td><td>0</td><td>NA</td><td>0</td></tr></tbody></table>

NA, not applicable since no resistant isolates were included.

<sup>a</sup>Categorized as susceptible (S) or susceptible, increased exposure (I) according to MIC.

<sup>b</sup>Categorized as resistant (R) according to MIC.

<sup>c</sup>Susceptible (S) or susceptible, increased exposure (I) with disc diffusion; resistant (R) with BMD.

<sup>d</sup>Resistant (R) with disc diffusion; susceptible (S) or susceptible, increased exposure (I) with BMD.

<table><caption>**Table 5.** Comparison of EUCAST and CLSI MIC breakpoints (mg/L) for *C. diphtheriae* and *C. ulcerans*</caption><thead><tr><th>Antimicrobial agent</th><th>EUCAST MIC<br>breakpoints<sup>a</sup><br>for C. diphtheriae<br>and<br>C. ulcerans<br>(S ≤ /R&gt;)</th><th>CLSI MIC breakpoints<sup>b</sup><br>for Corynebacterium spp.<br>including<br>C. diphtheriae<br>(S ≤ /R&gt;)</th></tr></thead><tbody><tr><td>Benzylpenicillin</td><td>0.001/1</td><td>0.125/2</td></tr><tr><td>Amoxicillin</td><td>1/1</td><td>—</td></tr><tr><td>Cefotaxime</td><td>0.001/2</td><td>1/2</td></tr><tr><td>Meropenem</td><td>0.25/0.25</td><td>0.25/0.5</td></tr><tr><td>Ciprofloxacin</td><td>0.001/0.5</td><td>1/2</td></tr><tr><td>Erythromycin</td><td>0.06/0.06</td><td>0.5/1</td></tr><tr><td>Clindamycin</td><td>0.5/0.5<sup>c</sup></td><td>0.5/2<sup>c</sup></td></tr><tr><td>Doxycycline</td><td>0.5/0.5</td><td>4/8</td></tr><tr><td>Tetracycline</td><td>1/1</td><td>4/8</td></tr><tr><td>Linezolid</td><td>2/2</td><td>2/1</td></tr><tr><td>Rifampicin</td><td>0.06/0.06</td><td>1/2</td></tr><tr><td>Trimethoprim/<br>sulfamethoxazole</td><td>0.5/0.5</td><td>2/2</td></tr></tbody></table>

<sup>a</sup>EUCAST Breakpoint Tables for Interpretation of MICs and Zone Diameters v. 13.1, 2023 and v. 14.0, 2024.

<sup>b</sup>CLSI M45—Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria. Third Edition, 2015. In this table, CLSI breakpoints are expressed in the EUCAST format (S≤, R≥) for comparison.

<sup>c</sup>Breakpoints apply to *C. diphtheriae* only.

This enables a penicillin screening testing strategy; since most isolates will be in the WT distribution for β-lactams, these can, without further testing, be reported as S to amoxicillin and meropenem and/or I to cefotaxime, based on the benzylpenicillin test result. Only the few benzylpenicillin-resistant isolates should then also be tested for other β-lactam agents. Similarly, tetracycline can be used to infer susceptibility to doxycycline.

This study has two limitations. First, the isolate collection comprised isolates from two neighbouring European countries. However, these were large collections of isolates, deduplicated with respect to epidemiological links, and it was shown that the phylogenetic diversity of surveillance isolates from these countries is highly representative of the global diversity of phylogenetic sublineages that circulate elsewhere.²²,²³ However, more geographically representative collections of isolates should be characterized in the future to confirm the WT MIC distributions that were found herein. Second, other species of the CdSC, including *C. pseudotuberculosis*, *C. belfantii*, *C. rouxii* and *C. silvaticum*, were not tested. These species either cause other infections (*C. pseudotuberculosis*), are tox negative (*C. rouxii* and *C. belfantii*) or are rare zoonotic non-toxigenic species (*C. silvaticum*). Given their phylogenetic and biological proximity, it can be expected that the proposed breakpoints for *C. diphtheriae* and *C. ulcerans* may be applied to these species too. However, future studies should test this hypothesis, as there might be exceptions, as illustrated here for clindamycin, which differs in its potency against *C. diphtheriae* and *C. ulcerans*.

Given the critical importance of antimicrobial therapy and prophylaxis in diphtheria clinical care and transmission control, and the increasing reporting of MDR tox-positive *C. diphtheriae* isolates,²²,²⁴,²⁵ the EUCAST breakpoints determined based on
the data of this work appear as a timely addition to the response against the resurgence of diphtheria. They should be useful to guide clinical handling of patients and their contacts, to harmonize surveillance data, and to prioritize outbreak control efforts towards limiting the spread of MDR C. diphtheriae sublineages.

## Acknowledgements

Parts of the results from this study have been presented as a poster at the 33rd ECCMID, Copenhagen, Denmark, 2023 (Ahman J, Brisse S, Badell E, Marosevic D, Berger A, Sing A, Matuschek E and Kahlmeter G, *Corynebacterium diphtheriae* and *C. ulcerans*—Development of clinical breakpoints using EUCAST methodology. Poster no. 0348).

The French participant laboratory authors would like to thank Annie Carmi-Leroy and Sylvie Brémont for expert laboratory assistance. The German participant laboratory authors thank Wolfgang Schmidt, Andrea Seifarth, Helga Kocak and Turgut-Cengiz Dedeoglu for expert laboratory assistance.

## Funding

The National Reference Center for Corynebacteria of the Diphtheriae Complex is supported financially by Santé publique France (Public Health France) and Institut Pasteur. The EUCAST Development Laboratory is supported by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). The German National Consiliary Laboratory on Diphtheria is supported by the German Federal Ministry of Health via the Robert Koch-Institute and its National Reference Laboratories Network (09-47, FKZ 1369-359). This research was funded, in whole or in part, by Institut Pasteur and Santé publique France. For the purpose of open access, the authors have applied a CC-BY public copyright license to any Author Manuscript version arising from this submission.

## Transparency declarations

The authors declare no conflicts of interest.

## Author contributions

J.À., E.M. and G.K. (EUCAST Development Laboratory) were responsible for study design, data analysis and QC of materials; J.À. produced the summary figures and tables; E.B. performed the experiments and produced the data in the French participant laboratory, with help from N.Z; A.B. performed the experiments and produced the data in the German participant laboratory; S.B. proposed the study, coordinated the French laboratory activities, and wrote the first draft of the manuscript with input from J.À; A.S. coordinated the German laboratory; all authors contributed to the writing of the manuscript and approved the final version.

## Supplementary data

Figures S1 to S3 and Table S1 are available as Supplementary data at JAC Online.

## References

1. Sharma NC, Efstratiou A, Mokrousov I et al. Diphtheria. *Nat Rev Dis Primers* 2019; **5**: 81. https://doi.org/10.1038/s41572-019-0131-y

2. Berger A, Dangel A, Schober T et al. Whole genome sequencing suggests transmission of *Corynebacterium diphtheriae*-caused cutaneous

diphtheria in two siblings, Germany, 2018. *Euro Surveill* 2019; **24**: 1800683. https://doi.org/10.2807/1560-7917.ES.2019.24.2.1800683

3. Kofler J, Ramette A, Iseli P et al. Ongoing toxin-positive diphtheria outbreaks in a federal asylum centre in Switzerland, analysis July to September 2022. *Euro Surveill* 2022; **27**: 2200811. https://doi.org/10.2807/1560-7917.ES.2022.27.44.2200811

4. Badenschier F, Berger A, Dangel A et al. Outbreak of imported diphtheria with *Corynebacterium diphtheriae* among migrants arriving in Germany, 2022. *Euro Surveill* 2022; **27**: 2200849. https://doi.org/10.2807/1560-7917.ES.2022.27.46.2200849

5. Hacker E, Antunes CA, Mattos-Guaraldi AL et al. *Corynebacterium ulcerans*, an emerging human pathogen. *Future Microbiol* 2016; **11**: 1191–208. https://doi.org/10.2217/fmb-2016-0085

6. Badell E, Alharazi A, Criscuolo A et al. Ongoing diphtheria outbreak in Yemen: a cross-sectional and genomic epidemiology study. *Lancet Microbe* 2021; **2**: e386–96. https://doi.org/10.1016/S2666-5247(21)00094-X

7. Polonsky JA, Ivey M, Mazhar MKA et al. Epidemiological, clinical, and public health response characteristics of a large outbreak of diphtheria among the Rohingya population in Cox's Bazar, Bangladesh, 2017 to 2019: a retrospective study. *PLoS Med* 2021; **18**: e1003587. https://doi.org/10.1371/journal.pmed.1003587

8. Adegboye OA, Alele FO, Pak A et al. A resurgence and re-emergence of diphtheria in Nigeria, 2023. *Ther Adv Infect Dis* 2023; **10**: 20499361231161936. https://doi.org/10.1177/20499361231161936

9. Hoefer A, Seth-Smith H, Palma F et al. Phenotypic and genomic analysis of a large-scale *Corynebacterium diphtheriae* outbreak among migrant populations in Europe. *medRxiv* 2023; 2023.11.10.23297228. https://doi.org/10.1101/2023.11.10.23297228

10. Bonmarin I, Guiso N, Le Flèche-Matéos A et al. Diphtheria: a zoonotic disease in France? *Vaccine* 2009; **27**: 4196–200. https://doi.org/10.1016/j.vaccine.2009.04.048

11. Wagner KS, White JM, Crowcroft NS et al. Diphtheria in the United Kingdom, 1986-2008: the increasing role of *Corynebacterium ulcerans*. *Epidemiol Infect* 2010; **138**: 1519–30. https://doi.org/10.1017/S0950268810001895

12. Dorella FA, Pacheco LGC, Oliveira SC et al. *Corynebacterium pseudotuberculosis*: microbiology, biochemical properties, pathogenesis and molecular studies of virulence. *Vet Res* 2006; **37**: 201–18. https://doi.org/10.1051/vetres:2005056

13. Dazas M, Badell E, Carmi-Leroy A et al. Taxonomic status of *Corynebacterium diphtheriae* biovar Belfanti and proposal of *Corynebacterium belfantii* sp. nov. *Int J Syst Evol Microbiol* 2018; **68**: 3826–31. https://doi.org/10.1099/ijsem.0.003069

14. Badell E, Hennart M, Rodrigues C et al. *Corynebacterium rouxii* sp. nov., a novel member of the *diphtheriae* species complex. *Res Microbiol* 2020; **171**: 122–7. https://doi.org/10.1016/j.resmic.2020.02.003

15. Dangel A, Berger A, Rau J et al. *Corynebacterium silvaticum* sp. nov., a unique group of NTTB corynebacteria in wild boar and roe deer. *Int J Syst Evol Microbiol* 2020; **70**: 3614–24. https://doi.org/10.1099/ijsem.0.004195

16. Crestani C, Arcari G, Landier A et al. *Corynebacterium ramonii* sp. nov., a novel toxigenic member of the *Corynebacterium diphtheriae* species complex. *Res Microbiol* 2023; **174**: 104113. https://doi.org/10.1016/j.resmic.2023.104113

17. Zou J, Chorlton SD, Romney MG et al. Phenotypic and genotypic correlates of penicillin susceptibility in nontoxigenic *Corynebacterium diphtheriae*, British Columbia, Canada, 2015–2018. *Emerging Infect Dis* 2020; **26**: 97–103. https://doi.org/10.3201/eid2601.191241

18. Marosevic DV, Berger A, Kahlmeter G et al. Antimicrobial susceptibility of *Corynebacterium diphtheriae* and *Corynebacterium ulcerans* in
the data of this work appear as a timely addition to the response against the resurgence of diphtheria. They should be useful to guide clinical handling of patients and their contacts, to harmonize surveillance data, and to prioritize outbreak control efforts towards limiting the spread of MDR C. diphtheriae sublineages.

## Acknowledgements

Parts of the results from this study have been presented as a poster at the 33rd ECCMID, Copenhagen, Denmark, 2023 (Ahman J, Brisse S, Badell E, Marosevic D, Berger A, Sing A, Matuschek E and Kahlmeter G, *Corynebacterium diphtheriae* and *C. ulcerans*—Development of clinical breakpoints using EUCAST methodology. Poster no. 0348).

The French participant laboratory authors would like to thank Annie Carmi-Leroy and Sylvie Brémont for expert laboratory assistance. The German participant laboratory authors thank Wolfgang Schmidt, Andrea Seifarth, Helga Kocak and Turgut-Cengiz Dedeoglu for expert laboratory assistance.

## Funding

The National Reference Center for Corynebacteria of the Diphtheriae Complex is supported financially by Santé publique France (Public Health France) and Institut Pasteur. The EUCAST Development Laboratory is supported by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). The German National Consiliary Laboratory on Diphtheria is supported by the German Federal Ministry of Health via the Robert Koch-Institute and its National Reference Laboratories Network (09-47, FKZ 1369-359). This research was funded, in whole or in part, by Institut Pasteur and Santé publique France. For the purpose of open access, the authors have applied a CC-BY public copyright license to any Author Manuscript version arising from this submission.

## Transparency declarations

The authors declare no conflicts of interest.

## Author contributions

J.À., E.M. and G.K. (EUCAST Development Laboratory) were responsible for study design, data analysis and QC of materials; J.À. produced the summary figures and tables; E.B. performed the experiments and produced the data in the French participant laboratory, with help from N.Z; A.B. performed the experiments and produced the data in the German participant laboratory; S.B. proposed the study, coordinated the French laboratory activities, and wrote the first draft of the manuscript with input from J.À; A.S. coordinated the German laboratory; all authors contributed to the writing of the manuscript and approved the final version.

## Supplementary data

Figures S1 to S3 and Table S1 are available as Supplementary data at JAC Online.

## References

1. Sharma NC, Efstratiou A, Mokrousov I et al. Diphtheria. *Nat Rev Dis Primers* 2019; **5**: 81. https://doi.org/10.1038/s41572-019-0131-y

2. Berger A, Dangel A, Schober T et al. Whole genome sequencing suggests transmission of *Corynebacterium diphtheriae*-caused cutaneous

diphtheria in two siblings, Germany, 2018. *Euro Surveill* 2019; **24**: 1800683. https://doi.org/10.2807/1560-7917.ES.2019.24.2.1800683

3. Kofler J, Ramette A, Iseli P et al. Ongoing toxin-positive diphtheria outbreaks in a federal asylum centre in Switzerland, analysis July to September 2022. *Euro Surveill* 2022; **27**: 2200811. https://doi.org/10.2807/1560-7917.ES.2022.27.44.2200811

4. Badenschier F, Berger A, Dangel A et al. Outbreak of imported diphtheria with *Corynebacterium diphtheriae* among migrants arriving in Germany, 2022. *Euro Surveill* 2022; **27**: 2200849. https://doi.org/10.2807/1560-7917.ES.2022.27.46.2200849

5. Hacker E, Antunes CA, Mattos-Guaraldi AL et al. *Corynebacterium ulcerans*, an emerging human pathogen. *Future Microbiol* 2016; **11**: 1191–208. https://doi.org/10.2217/fmb-2016-0085

6. Badell E, Alharazi A, Criscuolo A et al. Ongoing diphtheria outbreak in Yemen: a cross-sectional and genomic epidemiology study. *Lancet Microbe* 2021; **2**: e386–96. https://doi.org/10.1016/S2666-5247(21)00094-X

7. Polonsky JA, Ivey M, Mazhar MKA et al. Epidemiological, clinical, and public health response characteristics of a large outbreak of diphtheria among the Rohingya population in Cox's Bazar, Bangladesh, 2017 to 2019: a retrospective study. *PLoS Med* 2021; **18**: e1003587. https://doi.org/10.1371/journal.pmed.1003587

8. Adegboye OA, Alele FO, Pak A et al. A resurgence and re-emergence of diphtheria in Nigeria, 2023. *Ther Adv Infect Dis* 2023; **10**: 20499361231161936. https://doi.org/10.1177/20499361231161936

9. Hoefer A, Seth-Smith H, Palma F et al. Phenotypic and genomic analysis of a large-scale *Corynebacterium diphtheriae* outbreak among migrant populations in Europe. *medRxiv* 2023; 2023.11.10.23297228. https://doi.org/10.1101/2023.11.10.23297228

10. Bonmarin I, Guiso N, Le Flèche-Matéos A et al. Diphtheria: a zoonotic disease in France? *Vaccine* 2009; **27**: 4196–200. https://doi.org/10.1016/j.vaccine.2009.04.048

11. Wagner KS, White JM, Crowcroft NS et al. Diphtheria in the United Kingdom, 1986-2008: the increasing role of *Corynebacterium ulcerans*. *Epidemiol Infect* 2010; **138**: 1519–30. https://doi.org/10.1017/S0950268810001895

12. Dorella FA, Pacheco LGC, Oliveira SC et al. *Corynebacterium pseudotuberculosis*: microbiology, biochemical properties, pathogenesis and molecular studies of virulence. *Vet Res* 2006; **37**: 201–18. https://doi.org/10.1051/vetres:2005056

13. Dazas M, Badell E, Carmi-Leroy A et al. Taxonomic status of *Corynebacterium diphtheriae* biovar Belfanti and proposal of *Corynebacterium belfantii* sp. nov. *Int J Syst Evol Microbiol* 2018; **68**: 3826–31. https://doi.org/10.1099/ijsem.0.003069

14. Badell E, Hennart M, Rodrigues C et al. *Corynebacterium rouxii* sp. nov., a novel member of the *diphtheriae* species complex. *Res Microbiol* 2020; **171**: 122–7. https://doi.org/10.1016/j.resmic.2020.02.003

15. Dangel A, Berger A, Rau J et al. *Corynebacterium silvaticum* sp. nov., a unique group of NTTB corynebacteria in wild boar and roe deer. *Int J Syst Evol Microbiol* 2020; **70**: 3614–24. https://doi.org/10.1099/ijsem.0.004195

16. Crestani C, Arcari G, Landier A et al. *Corynebacterium ramonii* sp. nov., a novel toxigenic member of the *Corynebacterium diphtheriae* species complex. *Res Microbiol* 2023; **174**: 104113. https://doi.org/10.1016/j.resmic.2023.104113

17. Zou J, Chorlton SD, Romney MG et al. Phenotypic and genotypic correlates of penicillin susceptibility in nontoxigenic *Corynebacterium diphtheriae*, British Columbia, Canada, 2015–2018. *Emerging Infect Dis* 2020; **26**: 97–103. https://doi.org/10.3201/eid2601.191241

18. Marosevic DV, Berger A, Kahlmeter G et al. Antimicrobial susceptibility of *Corynebacterium diphtheriae* and *Corynebacterium ulcerans* in
Germany 2011-17. *J Antimicrob Chemother* 2020; **75**: 2885-93. https://doi.org/10.1093/jac/dkaa280

**19** EUCAST. Antimicrobial susceptibility testing: EUCAST disk diffusion method. Version 11.0. 2023. http://www.eucast.org/ast_of_bacteria/disk_diffusion_methodology/.

**20** Hennart M, Panunzi LG, Rodrigues C et al. Population genomics and antimicrobial resistance in *Corynebacterium diphtheriae*. *Genome Med* 2020; **12**: 107. https://doi.org/10.1186/s13073-020-00805-7

**21** Pereira GA, Pimenta FP, dos Santos FRW et al. Antimicrobial resistance among Brazilian *Corynebacterium diphtheriae* strains. *Mem Inst Oswaldo Cruz* 2008; **103**: 507-10. https://doi.org/10.1590/S0074-02762008000500019

**22** Hennart M, Crestani C, Bridel S et al. A global *Corynebacterium diphtheriae* genomic framework sheds light on current diphtheria

reemergence. *Peer Community J* 2023; **3**: e76. https://doi.org/10.24072/pcjournal.307

**23** Dangel A, Berger A, Konrad R et al. Geographically diverse clusters of nontoxigenic *Corynebacterium diphtheriae* infection, Germany, 2016-2017. *Emerging Infect Dis* 2018; **24**: 1239-45. https://doi.org/10.3201/eid2407.172026

**24** Forde BM, Henderson A, Playford EG et al. Fatal respiratory diphtheria caused by β-lactam-resistant *Corynebacterium diphtheriae*. *Clin Infect Dis* 2020; **73**: e4531-8. https://doi.org/10.1093/cid/ciaa1147

**25** Brémont S, Passet V, Hennart M et al. Multidrug-resistant *Corynebacterium diphtheriae* in people with travel history from West Africa to France, March to September 2023. *Euro Surveill* 2023; **28**: 2300615. https://doi.org/10.2807/1560-7917.ES.2023.28.46.2300615
Germany 2011-17. *J Antimicrob Chemother* 2020; **75**: 2885-93. https://doi.org/10.1093/jac/dkaa280

**19** EUCAST. Antimicrobial susceptibility testing: EUCAST disk diffusion method. Version 11.0. 2023. http://www.eucast.org/ast_of_bacteria/disk_diffusion_methodology/.

**20** Hennart M, Panunzi LG, Rodrigues C et al. Population genomics and antimicrobial resistance in *Corynebacterium diphtheriae*. *Genome Med* 2020; **12**: 107. https://doi.org/10.1186/s13073-020-00805-7

**21** Pereira GA, Pimenta FP, dos Santos FRW et al. Antimicrobial resistance among Brazilian *Corynebacterium diphtheriae* strains. *Mem Inst Oswaldo Cruz* 2008; **103**: 507-10. https://doi.org/10.1590/S0074-02762008000500019

**22** Hennart M, Crestani C, Bridel S et al. A global *Corynebacterium diphtheriae* genomic framework sheds light on current diphtheria

reemergence. *Peer Community J* 2023; **3**: e76. https://doi.org/10.24072/pcjournal.307

**23** Dangel A, Berger A, Konrad R et al. Geographically diverse clusters of nontoxigenic *Corynebacterium diphtheriae* infection, Germany, 2016-2017. *Emerging Infect Dis* 2018; **24**: 1239-45. https://doi.org/10.3201/eid2407.172026

**24** Forde BM, Henderson A, Playford EG et al. Fatal respiratory diphtheria caused by β-lactam-resistant *Corynebacterium diphtheriae*. *Clin Infect Dis* 2020; **73**: e4531-8. https://doi.org/10.1093/cid/ciaa1147

**25** Brémont S, Passet V, Hennart M et al. Multidrug-resistant *Corynebacterium diphtheriae* in people with travel history from West Africa to France, March to September 2023. *Euro Surveill* 2023; **28**: 2300615. https://doi.org/10.2807/1560-7917.ES.2023.28.46.2300615